NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Structure Therapeutics Inc. (GPCR) Stock Analysis

Structure Therapeutics Inc. (GPCR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GPCR

$22.01

−$0.87 (−3.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GPCR with… →

GPCR Key Statistics

As of Oct 21, 2026
Trading
Open
$23.00
Previous Close
$22.88
Day's Range
21.77–23.21
52-Week Range
20.73–94.90
Volume
804.08K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.37
Valuation
Market Cap
$1.57B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.03
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$141.20M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
71.31M
1-Year Return
−18.24%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GPCR closed at $22.01, −18.24% over 1 year.

Structure Therapeutics Inc. (GPCR) has a market capitalization of $1.57B.

In fiscal 2025, GPCR reported revenue of $0.00.

GPCR Stock Return by Calendar Year

Structure Therapeutics Inc. (GPCR) return since Feb 2023: what $10,000 became

1 year
$10,000 $8,176
−18.24%
3 years
$10,000 $3,260
−67.40%
Since Feb 2023
$10,000 $8,465
−15.35%

If you had invested $10,000 in Structure Therapeutics Inc. (GPCR) at the close on February 3, 2023, the earliest close on record here, it would have been worth $8,465 at the close on October 21, 2026: −15.35% in total, −4.39% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−68.35%
2025+156.45%
2024−33.46%
2023 (partial year)+56.77%

As of October 21, 2026.

GPCR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$141.20M—
2024$0.00−$122.53M—
2023$0.00−$89.62M—
2022$0.00−$51.32M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$186.81M−$141.20M—
2024$0.00—−$158.23M−$122.53M—
2023$0.00—−$102.78M−$89.62M—
2022$0.00—−$52.56M−$51.32M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Structure Therapeutics Inc. (GPCR) at $1.57B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 281.

GPCR last closed at $22.01 on October 21, 2026. That is −$0.87 (−3.80%) against the previous close. Over the past 52 weeks the price has ranged from $20.73 to $94.90. The latest close sits 6.2% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $141.20M. Earnings per share on a trailing basis come to −3.03.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −18.24%. Measured over 3 years, that is −31.18% a year compounded. Beta against the wider market is reported at −1.37. Annualized volatility over the trailing 3 years is 97.93%.

Growth & Income

No dividend is on file for GPCR.

2026 is still running; the total return is −68.35% year to date. Across the complete calendar years on file, 2025 returned +156.45% and 2024 returned −33.46%.

Peer Comparison

Structure Therapeutics Inc. (GPCR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Structure Therapeutics Inc. GPCR $1.57B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Structure Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit website →